MoonLake Immunotherapeutics
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jorge Santos da Silva
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Dorfstrasse 29 Zug Switzerland 6300
- IPO Date
- Oct 20, 2020
- CIK
- 0001821586
- Website
- moonlaketx.com
- Similar Companies
- Business
- MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Zug, Switzerland, focuses on developing next-generation Nanobody therapies targeting inflammatory skin and joint diseases driven by interleukins IL-17A and IL-17F; its lead candidate, Sonelokimab (SLK), is a novel tri-specific Nanobody that inhibits IL-17A/A, IL-17A/F, and IL-17F homodimers, advancing in Phase 3 trials including VELA-1 (NCT06411899) and VELA-2 (NCT06411379) for hidradenitis suppurativa (HS) in adults, VELA-TEEN for adolescent HS, and IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) for psoriatic arthritis (PsA), alongside Phase 2 programs such as LEDA for palmoplantar pustulosis (PPP), S-OLARIS for axial spondyloarthritis (axSpA), and P-OLARIS for PsA with axSpA overlap, with Phase 3-ready status for psoriasis (PsO). The company conducts global clinical trials to address unmet needs in dermatology and rheumatology patient populations. Recent developments include completion of enrollment in the Phase 3 VELA HS program with week-16 results reported in late 2025 prompting investor scrutiny and securities investigations, initiation of three new sonelokimab trials in early 2025 for adolescent HS, PPP, and axSpA, a $500 million non-dilutive financing agreement with Hercules Capital including $75 million drawn to fund operations through a potential 2027 launch, a three-year technology partnership with Komodo Health, and a $75 million offering to support sonelokimab research.
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know?
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Analysts
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Principal Financial Group Inc. Invests $509,000 in MoonLake Immunotherapeutics $MLTX